Despite improvements in progression-free survival and overall survival, the problems of relapsing and drug-resisting are still serious and long-term survival rates for patients with advanced epithelial ovarian carcinoma(EOC) remain disappointing.

• 患者无疾病进展生存时间及总生存时间得以改善,但复发和耐药问题依然严重,长期生存率并未提高。 最近,寻找一种与PTX、铂类均无交叉耐药且疗效确切的药物与之配伍治疗晚期卵巢癌成为热门研究课题。